Citations (101)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Abimael González-Hernández, Bruno A. Marichal-Cancino & Carlos M. Villalón. (2021) The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events. Expert Opinion on Drug Metabolism & Toxicology 17:10, pages 1223-1235.
Read now
Read now
Sang-Soo Kim, Joe B. Harford, Manish Moghe, Antonina Rait & Esther H. Chang. (2018) Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor. OncoImmunology 7:10.
Read now
Read now
Xiaohua Zhu, Mohamed Badawi, Steven Pomeroy, Dhruvitkumar S. Sutaria, Zhiliang Xie, Alice Baek, Jinmai Jiang, Ola A. Elgamal, Xiaokui Mo, Krista La Perle, Jeffrey Chalmers, Thomas D. Schmittgen & Mitch A. Phelps. (2017) Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. Journal of Extracellular Vesicles 6:1.
Read now
Read now
Benjamín Reyes-Beltrán & Gabriela Delgado. (2017) Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with Enbrel vs Etanar – Preliminary report. Journal of Immunotoxicology 14:1, pages 103-108.
Read now
Read now
Andrea Negro, Martina Curto, Luana Lionetto, Maria Adele Giamberardino & Paolo Martelletti. (2016) Chronic migraine treatment: from OnabotulinumtoxinA onwards. Expert Review of Neurotherapeutics 16:10, pages 1217-1227.
Read now
Read now
Poupak Fallahi, Silvia Martina Ferrari, Giusy Elia, Francesco Nasini, Michele Colaci, Dilia Giuggioli, Roberto Vita, Salvatore Benvenga, Clodoveo Ferri & Alessandro Antonelli. (2016) Novel Therapies for Thyroid Autoimmune Diseases. Expert Review of Clinical Pharmacology 9:6, pages 853-861.
Read now
Read now
Anette Karle, Sebastian Spindeldreher & Frank Kolbinger. (2016) Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. mAbs 8:3, pages 536-550.
Read now
Read now
H. Lebrec, M. B. Hock, J. S. Sundsmo, D. T. Mytych, H. Chow, L. L. Carlock, M. K. Joubert, J. Reindel, L. Zhou & J. L. Bussiere. (2014) T-cell-dependent antibody responses in the rat: Forms and sources of keyhole limpet hemocyanin matter. Journal of Immunotoxicology 11:3, pages 213-221.
Read now
Read now
Kamal Sharma, Ajay Kumar Mishra, Vikram Mehraj & Ganesh Selvaraj Duraisamy. (2014) Advances and applications of molecular cloning in clinical microbiology. Biotechnology and Genetic Engineering Reviews 30:1, pages 65-78.
Read now
Read now
Geertje J. D. van Mierlo, Nicole H. P. Cnubben, Diana Wouters, Gerrit Jan Wolbink, Margreet H. L. Hart, Theo Rispens, Niels-Christian Ganderup, C. Frieke Kuper, Lucien Aarden & André H. Penninks. (2014) The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab. Journal of Immunotoxicology 11:1, pages 62-71.
Read now
Read now
Peter J.K. van Meer, Marlous Kooijman, Vera Brinks, Christine C. Gispen-de Wied, Beatriz Silva-Lima, Ellen H.M. Moors & Huub Schellekens. (2013) Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. mAbs 5:5, pages 810-816.
Read now
Read now
Vladimir S. Yakopson & Joseph C. Flanagan. (2011) Postoperative Eyelid Infection in a Patient Taking Etanercept. Orbit 30:6, pages 303-304.
Read now
Read now
Frank R. Brennan, Laura Dill Morton, Sebastian Spindeldreher, Andrea Kiessling, Roy Allenspach, Adam Hey, Patrick Müller, Werner Frings & Jennifer Sims. (2010) Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. mAbs 2:3, pages 233-255.
Read now
Read now
Articles from other publishers (88)
Haider S. Mahdi, Mary Woodall-Jappe, Preeti Singh & Myron S. Czuczman. (2023) Targeting regulatory T cells by E7777 enhances CD8 T-cell–mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models. Frontiers in Immunology 14.
Crossref
Crossref
Krishna Khandelwal, Vedika Jajoo, Kshitij Bajpai, Bhushan Madke, Roshan Prasad, Mayur B Wanjari, Pratiksha K Munjewar & Avinash B Taksande. (2023) Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology. Cureus.
Crossref
Crossref
Alessandra Monti, Luigi Vitagliano, Andrea Caporale, Menotti Ruvo & Nunzianna Doti. (2023) Targeting Protein–Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches. International Journal of Molecular Sciences 24:9, pages 7842.
Crossref
Crossref
Michael Chary, Alexander F. Barbuto, Sudeh Izadmehr, Marc Tarsillo, Eduardo Fleischer & Michele M. Burns. (2023) COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics). Journal of Medical Toxicology 19:2, pages 205-218.
Crossref
Crossref
John Yeh. (2023) Harnessing Immunologic Tools to Treat Gynecologic Disorders. Current Women s Health Reviews 19:2.
Crossref
Crossref
Michael W. Leach & Katherine Hammerman. 2023. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology
175
230
.
Elisa Guidotti, Chiara Seghieri, Bruna Vinci, Alice Borghini & Francesco Attanasio. (2022) Monitoring Appropriate Monoclonal Antibodies Prescribing via Administrative Data: An Application to Psoriasis. Pharmaceuticals 15:10, pages 1238.
Crossref
Crossref
Ji Eun Yu, In Jun Yeo, Dong Ju Son, Jaesuk Yun, Sang‐Bae Han & Jin Tae Hong. (2021) Anti‐Chi3L1 antibody suppresses lung tumor growth and metastasis through inhibition of M2 polarization. Molecular Oncology 16:11, pages 2214-2234.
Crossref
Crossref
Rachel Melendez, Benjamin Ordonia, Joyce Guerrero, Azadeh Hassanzadeh, Peter Tran, Justin Low, Manda Wong, Jochen Brumm, Shan Chung & Lynn Kamen. (2022) Introducing dendritic cell antibody internalization as an immunogenicity risk assessment tool. Bioanalysis 14:10, pages 703-713.
Crossref
Crossref
Irene Campi, Guia Vannucchi, Ilaria Muller, Elisa Lazzaroni, Nicola Currò, Martina Dainese, Benedetta Montacchini, Danila Covelli, Claudio Guastella, Lorenzo Pignataro, Laura Fugazzola, Maura Arosio & Mario Salvi. (2022) Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy. Frontiers in Endocrinology 12.
Crossref
Crossref
Cathy Nguyen & Lars Petter Jordheim. (2023) Évaluation de l’immunotoxicité en recherche et dans le cadre du développement biomédical. Biologie Aujourd’hui 216:3-4, pages 167-181.
Crossref
Crossref
Syahrul Sazliyana Shaharir, Nor Adzimah Johdi & Rozita Mohd. 2022. Encyclopedia of Infection and Immunity. Encyclopedia of Infection and Immunity
741
754
.
Tamara G. Dacoba, Shubaash Anthiya, Germán Berrecoso, Iago Fernández‐Mariño, Carmen Fernández‐Varela, José Crecente‐Campo, Desirée Teijeiro‐Osorio, Fernando Torres Andón & María J. Alonso. (2021) Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues. Advanced Functional Materials 31:44, pages 2009860.
Crossref
Crossref
Chris Floyd & Martin Crook. (2021) Adverse events to PCSK-9 inhibitors: what is the current evidence?. Postgraduate Medical Journal 97:1150, pages 485-486.
Crossref
Crossref
Alexander Batista-Duharte, Alejandra Pera, Salvador F. Aliño & Rafael Solana. (2021) Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects. International Immunopharmacology 96, pages 107761.
Crossref
Crossref
Zeru Tian, Ling Wu, Chenfei Yu, Yuda Chen, Zhan XuIgor BadoAxel Loredo, Lushun Wang, Hai WangKuan-Lin Wu, Weijie Zhang, Xiang H.-F. Zhang & Han Xiao. (2021) Harnessing the power of antibodies to fight bone metastasis. Science Advances 7:26.
Crossref
Crossref
Wei Zhan, Manish Muhuri, Phillip W. L. Tai & Guangping Gao. (2021) Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?. Frontiers in Immunology 12.
Crossref
Crossref
Pietro Speziale & Giampiero Pietrocola. (2021) Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci. Vaccines 9:5, pages 459.
Crossref
Crossref
M. Fernando Bravo, Manuel A. Lema, Mateusz Marianski & Adam B. Braunschweig. (2020) Flexible Synthetic Carbohydrate Receptors as Inhibitors of Viral Attachment. Biochemistry 60:13, pages 999-1018.
Crossref
Crossref
Sean D. Allen, Xiangsheng Liu, Jinhong Jiang, Yu-Pei Liao, Chong Hyun Chang, Andre E. Nel & Huan Meng. (2021) Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor. Biomaterials 269, pages 120635.
Crossref
Crossref
Thomas J. Esparza, Negin P. Martin, George P. Anderson, Ellen R. Goldman & David L. Brody. (2020) High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. Scientific Reports 10:1.
Crossref
Crossref
Siratcha Phanthong, Jaslan Densumite, Watee Seesuay, Jeeraphong Thanongsaksrikul, Salma Teimoori, Nitat Sookrung, Yong Poovorawan, Napa Onvimala, Ratigorn Guntapong, Kovit Pattanapanyasat & Wanpen Chaicumpa. (2020) Human Antibodies to VP4 Inhibit Replication of Enteroviruses Across Subgenotypes and Serotypes, and Enhance Host Innate Immunity. Frontiers in Microbiology 11.
Crossref
Crossref
Labe A. Black & Tatiana Zorina. (2020) Genetic profile considerations for induction of allogeneic chimerism as a therapeutic approach for type 1 diabetes mellitus. Drug Discovery Today 25:8, pages 1293-1297.
Crossref
Crossref
Ramesh Thevendran, Shigdar Sarah, Thean-Hock Tang & Marimuthu Citartan. (2020) Strategies to bioengineer aptamer-driven nanovehicles as exceptional molecular tools for targeted therapeutics: A review. Journal of Controlled Release 323, pages 530-548.
Crossref
Crossref
Michael A. Chary, Alexander F. Barbuto, Sudeh Izadmehr, Bryan D. Hayes & Michele M. Burns. (2020) COVID-19: Therapeutics and Their Toxicities. Journal of Medical Toxicology 16:3, pages 284-294.
Crossref
Crossref
Yam Nath Paudel, Efthalia Angelopoulou, Christina Piperi, Iekhsan Othman & Mohd. Farooq Shaikh. (2020) HMGB1-Mediated Neuroinflammatory Responses in Brain Injuries: Potential Mechanisms and Therapeutic Opportunities. International Journal of Molecular Sciences 21:13, pages 4609.
Crossref
Crossref
Rakesh Bam, Patrick S. Lown, Lawrence A. Stern, Karina Sharma, Katheryne E. Wilson, Gregory R. Bean, Amelie M. Lutz, Ramasamy Paulmurugan, Benjamin J. Hackel, Jeremy Dahl & Lotfi Abou-Elkacem. (2020) Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection. Clinical Cancer Research 26:9, pages 2140-2150.
Crossref
Crossref
Atul Deodhar, Dafna D. Gladman, Iain B. McInnes, Sebastian Spindeldreher, Ruvie Martin, Luminita Pricop, Brian Porter, Jorge SafiJr.Jr., Abhijit Shete & Gerard Bruin. (2020) Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. The Journal of Rheumatology 47:4, pages 539-547.
Crossref
Crossref
Jessica M. Pouso-Diz, Jose M. Abalo-Lojo & Francisco Gonzalez. (2020) Thyroid eye disease: current and potential medical management. International Ophthalmology 40:4, pages 1035-1048.
Crossref
Crossref
Kai Le, Shanshan Wu, Enkhmurun Chibaatar, Abdoulaye Idriss Ali & Yijing Guo. (2020) Alarmin HMGB1 Plays a Detrimental Role in Hippocampal Dysfunction Caused by Hypoxia-Ischemia Insult in Neonatal Mice: Evidence from the Application of the HMGB1 Inhibitor Glycyrrhizin. ACS Chemical Neuroscience 11:6, pages 979-993.
Crossref
Crossref
László Vécsei, Melinda Lukács, János Tajti, Ferenc Fülöp, József Toldi & Lars Edvinsson. (2019) The Therapeutic Impact of New Migraine Discoveries. Current Medicinal Chemistry 26:34, pages 6261-6281.
Crossref
Crossref
Kyria M. Webster, Sandy R. Shultz, Ezgi Ozturk, Larissa K. Dill, Mujun Sun, Pablo Casillas-Espinosa, Nigel C. Jones, Peter J. Crack, Terence J. O'Brien & Bridgette D. Semple. (2019) Targeting high-mobility group box protein 1 (HMGB1) in pediatric traumatic brain injury: Chronic neuroinflammatory, behavioral, and epileptogenic consequences. Experimental Neurology 320, pages 112979.
Crossref
Crossref
Cecilie Knudsen, Line Ledsgaard, Rasmus Ibsen Dehli, Shirin Ahmadi, Christoffer Vinther Sørensen & Andreas Hougaard Laustsen. (2019) Engineering and design considerations for next-generation snakebite antivenoms. Toxicon 167, pages 67-75.
Crossref
Crossref
Sara García Gil, Fernando Gutiérrez Nicolás, Guillermo A González De La Fuente, Gloria J Nazco Casariego, M Micaela Viña Romero & J Norberto Batista López. (2019) Ten-minute administration of bevacizumab. European Journal of Hospital Pharmacy 26:4, pages 218-219.
Crossref
Crossref
Joannes A. A. Reijers, Karen E. Malone, Jeffrey J. Bajramovic, Richard Verbeek, Jacobus Burggraaf & Matthijs Moerland. (2019) Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals. British Journal of Clinical Pharmacology 85:7, pages 1418-1426.
Crossref
Crossref
Farhanah Aziz, Muneera Smith & Jonathan M Blackburn. 2019. Autoantibodies and Cytokines. Autoantibodies and Cytokines.
Elizabeth A. Insull, Zuzana Sipkova, Joel David, Helen E. Turner & Jonathan H. Norris. (2019) Early low‐dose rituximab for active thyroid eye disease: An effective and well‐tolerated treatment. Clinical Endocrinology.
Crossref
Crossref
Dirk Thomas, Kirstin Thelen, Stefanie Kraff, Stephan Schwers, Sonja Schiffer, Sigrun Unger, Ashraf Yassen & Stefanie Boxnick. (2019) BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics. Research and Practice in Thrombosis and Haemostasis 3:2, pages 242-253.
Crossref
Crossref
Muhammed T. Gürgöze, Annemarie H.G. Muller‐Hansma, Michelle M. Schreuder, Annette M.H. Galema‐Boers, Eric Boersma & Jeanine E. Roeters van Lennep. (2018)
Adverse Events Associated With
PCSK
9 Inhibitors: A Real‐World Experience
. Clinical Pharmacology & Therapeutics 105:2, pages 496-504.
Crossref
Crossref
Tiene Bauters & Johan Vandenbroucke. (2017) Development of a flowchart for risk assessment and allocation of preparation of monoclonal antibodies. Journal of Oncology Pharmacy Practice 25:1, pages 187-191.
Crossref
Crossref
J. Posner, P. Barrington, T. Brier & A. Datta-Mannan. 2019. Concepts and Principles of Pharmacology. Concepts and Principles of Pharmacology
81
141
.
Morris Levin, Stephen D. Silberstein, Robert Gilbert, Sylvia Lucas, Leanne Munsie, Alyssa Garrelts, Kate Kennedy, Nicole Everman & Eric Pearlman. (2018) Basic Considerations for the Use of Monoclonal Antibodies in Migraine. Headache: The Journal of Head and Face Pain 58:10, pages 1689-1696.
Crossref
Crossref
Nazia Karsan, Jonathan Jia Yuan Ong & Peter Goadsby. (2018) Emerging Treatment Options in Migraine. EMJ Neurology, pages 50-58.
Crossref
Crossref
Koen Paemeleire & Antoinette MaassenVanDenBrink. (2018) Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Current Opinion in Neurology 31:3, pages 274-280.
Crossref
Crossref
Andreas H. Laustsen, José María Gutiérrez, Cecilie Knudsen, Kristoffer H. Johansen, Erick Bermúdez-Méndez, Felipe A. Cerni, Jonas A. Jürgensen, Line Ledsgaard, Andrea Martos-Esteban, Mia Øhlenschlæger, Urska Pus, Mikael R. Andersen, Bruno Lomonte, Mikael Engmark & Manuela B. Pucca. (2018) Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon 146, pages 151-175.
Crossref
Crossref
Tamás Fülöp, Tamás Mészáros, Gergely Kozma, János Szebeni & Mihály Józsi. (2018) Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H. Antibodies 7:1, pages 14.
Crossref
Crossref
Jonathan Jia Yuan Ong, Diana Yi-Ting Wei & Peter J. Goadsby. (2018) Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs 78:4, pages 411-437.
Crossref
Crossref
Sebastian Spindeldreher, Bernard Maillère, Evelyne Correia, Maxime Tenon, Anette Karle, Philip Jarvis & Frank Kolbinger. (2018) Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab. Dermatology and Therapy 8:1, pages 57-68.
Crossref
Crossref
Muhamad Che Nordin & Sin-Yeang Teow. (2018) Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy. Molecules 23:2, pages 335.
Crossref
Crossref
A.L. Kimzey, M-S Piche, M Wood, AB. Weir & J Lansita. 2018. Comprehensive Toxicology. Comprehensive Toxicology
399
427
.
Emma Hays, Wei Duan & Sarah Shigdar. (2017) Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications. International Journal of Molecular Sciences 18:12, pages 2576.
Crossref
Crossref
Lanfranco Pellesi, Simona Guerzoni & Luigi Alberto Pini. (2017) Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clinical Pharmacology in Drug Development 6:6, pages 534-547.
Crossref
Crossref
Azadeh Nilghaz, Evan Trofimchuk & Xiaonan Lu. 2017. Sensing Techniques for Food Safety and Quality Control. Sensing Techniques for Food Safety and Quality Control
121
140
.
K. Reich, A. BlauveltA. ArmstrongR.G. Langley, T. Fox, J. HuangC. Papavassilis, E. Liang, P. Lloyd & G. Bruin. (2017) Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology 176:3, pages 752-758.
Crossref
Crossref
Joy Bartholomew, Tanea Washington, Sharon Bergeron, Danelle Nielson, Jennifer Saggio & Lindsay Quirk. (2016) Dinutuximab. Journal of Pediatric Oncology Nursing 34:1, pages 5-12.
Crossref
Crossref
Molly H. Boyle. 2017. Immunopathology in Toxicology and Drug Development. Immunopathology in Toxicology and Drug Development
455
477
.
Joanna MacdonaldPatrick HoughtonDongxi XiangWei DuanSarah Shigdar. (2016) Truncation and Mutation of a Transferrin Receptor Aptamer Enhances Binding Affinity. Nucleic Acid Therapeutics 26:6, pages 348-354.
Crossref
Crossref
Ann Haerskjold, Marie Linder, Lonny Henriksen, Simon Francis Thomsen, Helle Kieler, Henrik Ravn & Lone Graff Stensballe. (2016) Palivizumab Exposure and the Risk of Autoimmune Disease: A Cross-National Cohort Study. Pediatric Drugs 18:6, pages 435-441.
Crossref
Crossref
Irene Campi, Guia Vannucchi & Mario Salvi. (2016) THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves’ orbitopathy. European Journal of Endocrinology 175:3, pages R117-R133.
Crossref
Crossref
Bernd Jilma & Markus Müller. 2016. Clinical Pharmacology: Current Topics and Case Studies. Clinical Pharmacology: Current Topics and Case Studies
305
315
.
Dimos D. Mitsikostas & Alan M. Rapoport. (2015) New players in the preventive treatment of migraine. BMC Medicine 13:1.
Crossref
Crossref
Theresa Frenz, Elena Grabski, Verónica Durán, Constantin Hozsa, Anna Stępczyńska, Marcus Furch, Robert K. Gieseler & Ulrich Kalinke. (2015) Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers. European Journal of Pharmaceutics and Biopharmaceutics 95, pages 13-17.
Crossref
Crossref
Nazia Karsan & Peter J. Goadsby. (2015) Calcitonin gene-related peptide and migraine. Current Opinion in Neurology 28:3, pages 250-254.
Crossref
Crossref
Sandhya Jinesh. (2015) Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology 23:2-3, pages 71-77.
Crossref
Crossref
Madhur D. Shastri, Niall Stewart, James Horne, Gregory M. Peterson, Nuri Gueven, Sukhwinder S. Sohal & Rahul P. Patel. (2015) In-Vitro Suppression of IL-6 and IL-8 Release from Human Pulmonary Epithelial Cells by Non-Anticoagulant Fraction of Enoxaparin. PLOS ONE 10:5, pages e0126763.
Crossref
Crossref
Nazia Karsan & Peter J. Goadsby. (2015) CGRP Mechanism Antagonists and Migraine Management. Current Neurology and Neuroscience Reports 15:5.
Crossref
Crossref
Mario Salvi & Guia Vannucchi. 2015. Graves' Disease. Graves' Disease
317
336
.
Mario Salvi, Richard L. Scawn, Roman Farjardo, Bobby S. Korn & Don O. Kikkawa. 2015. Thyroid Eye Disease. Thyroid Eye Disease
89
97
.
Mario Salvi. (2014) Immunotherapy for Graves’ ophthalmopathy. Current Opinion in Endocrinology, Diabetes & Obesity 21:5, pages 409-414.
Crossref
Crossref
Liangbiao George Hu & David W. Clarke. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
26
.
David Eastwood, Chris Bird, Paula Dilger, Jason Hockley, Lucy Findlay, Stephen Poole, Susan J. Thorpe, Meenu Wadhwa, Robin Thorpe & Richard Stebbings. (2013)
Severity of the
TGN
1412 trial disaster cytokine storm correlated with
IL
‐2 release
. British Journal of Clinical Pharmacology 76:2, pages 299-315.
Crossref
Crossref
Vasileios Askoxylakis, Annabell Marr, Annette Altmann, Annette Markert, Walter Mier, Jürgen Debus, Peter E. Huber & Uwe Haberkorn. (2012) Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor Beta. Molecular Imaging and Biology 15:2, pages 212-221.
Crossref
Crossref
Padma Kumar Narayanan, Rafael Ponce & Beth Hinkle. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
65
95
.
Jennifer G. Brown. 2013. A Comprehensive Guide to Toxicology in Preclinical Drug Development. A Comprehensive Guide to Toxicology in Preclinical Drug Development
479
488
.
John T. Farmer & Rodney R. Dietert. 2013. A Comprehensive Guide to Toxicology in Preclinical Drug Development. A Comprehensive Guide to Toxicology in Preclinical Drug Development
365
381
.
Dimitry M. Danilenko & Hong Wang. (2012) The Yin and Yang of Immunomodulatory Biologics: Assessing the Delicate Balance between Benefit and Risk. Toxicologic Pathology 40:2, pages 272-287.
Crossref
Crossref
Heather H. Shih. 2012. Development of Antibody-Based Therapeutics. Development of Antibody-Based Therapeutics
9
32
.
D. J. Snodin & A. Suitters. 2011. Stephens' Detection and Evaluation of Adverse Drug Reactions. Stephens' Detection and Evaluation of Adverse Drug Reactions
157
214
.
Genc Basha, Tatiana I Novobrantseva, Nicole Rosin, Yuen Yi C Tam, Ismail M Hafez, Matthew K Wong, Tsukasa Sugo, Vera M Ruda, June Qin, Boris Klebanov, Marco Ciufolini, Akin Akinc, Ying K Tam, Michael J Hope & Pieter R Cullis. (2011) Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells. Molecular Therapy 19:12, pages 2186-2200.
Crossref
Crossref
Lefkothea C. Papadopoulou & Asterios S. Tsiftsoglou. (2011) Transduction of Human Recombinant Proteins into Mitochondria as a Protein Therapeutic Approach for Mitochondrial Disorders. Pharmaceutical Research 28:11, pages 2639-2656.
Crossref
Crossref
Paul Chamberlain. (2011) Pre-clinical strategies and safety issues in developing therapeutic monoclonal antibodies. New Biotechnology 28:5, pages 481-488.
Crossref
Crossref
Susan Kirshner. 2011. Detection and Quantification of Antibodies to Biopharmaceuticals. Detection and Quantification of Antibodies to Biopharmaceuticals
13
35
.
Sarah A. Goodchild, Lyn M. O?Brien, John Steven, Mischa R. Muller, Oliver J. Lanning, Christopher H. Logue, Riccardo V. D?Elia, Robert J. Phillpotts & Stuart D. Perkins. (2011) A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus. Antiviral Research 90:1, pages 1-8.
Crossref
Crossref
Frederic Zoller, Uwe Haberkorn & Walter Mier. (2011) Miniproteins as Phage Display-Scaffolds for Clinical Applications. Molecules 16:3, pages 2467-2485.
Crossref
Crossref
Vasileios Askoxylakis, Sabine Zitzmann-Kolbe, Frederic Zoller, Annette Altmann, Annette Markert, Shoaib Rana, Annabell Marr, Walter Mier, Jürgen Debus & Uwe Haberkorn. (2011) Challenges in Optimizing a Prostate Carcinoma Binding Peptide, Identified through the Phage Display Technology. Molecules 16:2, pages 1559-1578.
Crossref
Crossref
Satish Kumar Singh. (2011) Impact of Product-Related Factors on Immunogenicity of Biotherapeutics. Journal of Pharmaceutical Sciences 100:2, pages 354-387.
Crossref
Crossref
Sha-luo Li, Yong-hua Xu, Xi Wang, Xue-feng Liu & Liang Zhao. (2011) Effects of enteral immunonutrition on immune function in patients with multiple trauma. World Journal of Emergency Medicine 2:3, pages 206.
Crossref
Crossref
Valeria Bruno, Giuseppe Battaglia & Ferdinando Nicoletti. (2010) The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurological Sciences 31:S3, pages 283-288.
Crossref
Crossref